Increased Mortality by Septicemia, Interstitial Pneumonitis and Pulmonary Fibrosis Among Bone Marrow Transplant Recipients Receiving an Increased Mean Dose Rate of Total Irradiation

“…8 From 1999, TBI was given fractionated (fTBI) 3 Gy/day for 4 days. 9 As an alternative, 80 patients received a combination of busulphan (Bu) (4 mg/kg/day Â 4) and Cy (60 mg/kg Â 2).…”

Section: Conditioningmentioning

confidence: 99%

Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease

Mattsson

Westin

Edlund

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

“…24 Two patients received busulfan (BU) 4 mg/kg on 4 consecutive days, followed by CY 60 mg/kg for 2 days. 25 One patient with severe aplastic anemia (SAA) received CY and antithymocyte globulin (ATG).…”

Section: Conditioning and Prophylaxis Against Gvhdmentioning

confidence: 99%

“…23 Sixty-six patients were treated with cyclophosphamide (CY) 60 mg/kg for 2 consecutive days, in combination with total body irradiation (TBI) in a total dose of 10 Gy in a single fraction, and 9 Gy in the pulmonary region at a dose rate of 4 cGy/min. 24 Two patients received busulfan (BU) 4 mg/kg on 4 consecutive days, followed by CY 60 mg/kg for 2 days. 25 One patient with severe aplastic anemia (SAA) received CY and antithymocyte globulin (ATG).…”

Section: Conditioning and Prophylaxis Against Gvhdmentioning

confidence: 99%

A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation

Hägglund

Ringdén

Oman

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:A study was done to compare treatment with Filgrastim (r-metHuG-CSF) given at three different times after unrelated bone marrow transplantation (BMT). Sixtynine patients grafted with HLA-A, -B and -DR-compatible unrelated bone marrow were randomized to Filgrastim (5 g/kg/day) starting on day 0 (n = 23), day +5 (n = 23) or day +10 (n = 23) after BMT. No significant differences were detected in hematological recovery, days with fever, days on antibiotics, incidence of bacteremia or need for erythrocyte, platelet and granulocyte transfusions between the three groups. Patients given Filgrastim starting on day 0, day +5 or day +10, respectively, reached an absolute neutrophil count (ANC) Ͼ Ͼ Ͼ0.5 ؋ 10 9 /l on a median of 17, 16 and 16 days after BMT. Starting Filgrastim treatment on day +10, rather than on day 0, reduced the costs of Filgrastim by $1060, with no significant change in the median number of days-tohospital discharge in the three Filgrastim-treated groups. The incidences of acute and chronic GVHD, transplantation-related mortality, relapse, leukemiafree survival and patient survival (PS) were similar in all groups. Keywords: BMT; unrelated donors; G-CSF; engraftment During the past few years, hematopoietic stem cells (HSC) from unrelated donors have been increasingly used for transplantation.1,2 Almost 4 million volunteer donors of HSC are available worldwide. Therefore, one can find an HLA-A, -B and -DR-identical donor for approximately 70% of all Caucasian patients who need an allogeneic hematopoietic stem cell transplant (HSCT). If unrelated HSC are used, there is an increased risk of acute graft-versushost disease (GVHD), infections and a higher transplantrelated mortality.3,4 It is well established that recombinant human granulocyte-macrophage and granulocyte colonystimulating factors (rHuGM-CSF, rHuG-CSF) can accelerate neutrophil recovery after treatment with chemotherapy and autologous or allogeneic HSCT. penia, and some studies a reduction in the duration of antibiotic treatment, infections and the length of hospitalization.13-18 Experience of G-CSF treatment after unrelated BMT is limited. [19][20][21][22] The present study compares initiation of Filgrastim (r-metHuG-CSF) treatment at 0, +5 or +10 days after HLA-A,-B and -DR-compatible unrelated HSCT. Patients and methods PatientsThe protocol was approved by the local ethics review committee at Huddinge Hospital, and all patients gave informed consent before the study. Sixty-nine consecutive patients receiving bone marrow from HLA-A, -B and -DR-compatible unrelated donors between April 1994 and September 1997 were studied. The patients were stratified for children Ͻ18 years and adults у18 years, and for patients with or without malignancies. Patients were randomized to receive Filgrastim treatment starting on day 0, day +5 or day +10. Conditioning and prophylaxis against GVHDThe conditioning regimen and graft-versus-host disease (GVHD) prophylaxis were the same throughout the study period.23 Sixty-six patients were treated with cyclopho...

show abstract

Increased Mortality by Septicemia, Interstitial Pneumonitis and Pulmonary Fibrosis Among Bone Marrow Transplant Recipients Receiving an Increased Mean Dose Rate of Total Irradiation

Cited by 37 publications

References 17 publications

Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow

Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow

Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease

A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation

Contact Info

Product

Resources

About